Neumora Therapeutics IPO Presentation Deck

Differentiated IP Position Includes Composition of Matter Protection with Favorable Expiration Dates Across Programs and Process Protection for Precision Platform Target Neurodegen Neuropsychiatry erative Navacaprant (NMRA-140)(1) KOR Antagonist NMRA-511 V1aR Antagonist NMRA-266(1) M4R PAM NMRA-NMDA NMDA PAM NMRA-CK18 Ck16 Inhibitor NMRA-NLRP3 NLRP3 NMRA-GCASE GCase *All dates are approximate / estimates / projections only PTE = US patent term extension +Estimates do not include PTE Portfolio of Drugs All new chemical entities Composition of matter patents for each program Favorable expiration dates Composition of Matter Patent Status US + Foreign Patents Issued US Patent Issued Foreign Patent Applications Pending US and Foreign Patents Pending Patent Pending Patent Pending Multiple Patents Pending In process Precision Platform AI/ML approach to find higher responding patients High-level, AI/ML process patent protection for Data Processing, Patient Stratification and Target / Drug Discovery + Translation Trade secret protection of underlying details Base Patent Expiration / Patent Expiration with PTE* 2038 / 2041 2038 / 2043 2041 / 2042 Pending (2044+) Pending (2043+) Pending (2043+) Pending (2044+) Biomarkers Approximate higher responding clusters Method of treatment patent protection Cover selecting patients with biomarker and treating with drug/class

View entire presentation